Net sales were $188.6 million, a 7.7% year-over-year increase, according to a news release. Orthofix’s bone growth therapies segment grew 10% year-over-year, and this has been the fifth consecutive quarter with double-digit growth in that area.
Global orthopedic sales were $27.3 million, an increase of 5.1% year-over-year. Global spine sales grew 8.1% year-over-year with $161.3 million.
Orthofix saw a net loss of $36 million. The company is projecting 2024 sales between $790 million to $795 million.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.